Skip to content
A person in a white protective suit and cap sits at a robotic surgical console in a hospital room, leaning into the viewer hood with their hands on the master controls and the foot pedals below.

In Healthcare

FDA opens discussion paper on autonomous and teleoperated robotic devices

Image: Staff Sgt. Bernardo Fuller, via Wikimedia Commons (public domain) · public-domain

Published · North America

The FDA device centre published a discussion paper on the benefit and risk of robots that act with autonomy or remote control; comments close on 5 January 2027.

The U.S. Food and Drug Administration's Center for Devices and Radiological Health published a discussion paper in November 2026, with its web page current as of 6 November. It is titled Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities.

The paper covers robotic devices that perform diagnostic, therapeutic or rehabilitative tasks on human anatomy with some autonomy, remote teleoperation, or both. It addresses current and future devices, surgical and non-surgical, and users from imaging technicians to surgeons. Its topics are terminology, the benefits and risks of autonomous capabilities, the benefits and risks of remote teleoperation, and risk mitigations.

The FDA states that the paper is for discussion only. It is not draft or final guidance, does not propose policy changes and does not set out the agency's regulatory expectations. Comments are open until 5 January 2027 under docket FDA-2026-N-13135 on Regulations.gov.

Sources

On RobotShop

Professional Service Robots